Paricalcitol Catalog No.:M10243-10 as well as U1242 cells

as well as U1242 cells by >50% and ~60% respectively

7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide

164658-13-3

Smiles: OC[C@H]1O[C@@H](OC2C=C(O)C=C(C=2)/C=C/C2C=CC(O)=CC=2)[C@H](O)[C@@H](O)[C@@H]1O

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

Paricalcitol Catalog No.:M10243-10 as well as U1242 cellsParicalcitol, marketed by Abbott Laboratories under the trade name Zemplar, is a drug used for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. It is an analog of 1,25 dihydroxyergocalciferol, the active form of vitamin D2. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin